刘利江,刘辉

• 1:九江学院体育学院
• 2:九江学院体育学院 江西九江332005
• 3:江西九江332005

摘要(Abstract)：

基因兴奋剂是指非治疗目的使用提高运动能力的基因、遗传构件和(或)细胞.现在的基因兴奋剂主要是与有氧耐力和身体力量相关的基因兴奋剂,与速度相关的基因兴奋剂很少涉及.新兴奋剂的不断出现,使国际反兴奋剂组织不断制定出相应的反兴奋剂法律法规,《反兴奋剂国际公约》由此应运而生.我国在反兴奋剂方面也取得了明显的成绩.

关键词(KeyWords)： 基因;兴奋剂;《反兴奋剂国际公约》

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 刘利江,刘辉

参考文献(References)：

• [1]GALLAGHER R.The straight dope on gene doping[J].Scientist,2005,19(5):6.
• [2]PINCOCK S.Feature-Gene doping[J].Lancet,2005,366(Supplement 1):18~19.
• [3]DIAMANTI-KA NDARAKIS E,KONSTANTINOPOULOS P A,PAPAILIOU J,et al.Erythropoietin abuse anderythropoietin gene doping-Detection strategies in the genomic era[J].Sports Medicine,2005,35(10):831~840.
• [4]VERMA I M.Doping,gene transfer and sport[J].Molecular Therapy,2004,10(3):405.
• [5]SVENSSON E,BLACK H,DUGGER D.Long term erythropoietin expression in rodents and non-human primates followingintramuscular injection of a replication-defective adenoviral vector[J].Human Gene Therapy,1997,8(15):1797~1806.
• [6]LEE M S,LEE J S,LEE J Y.Prevention of erythropoietin-associated hypertension[J].Hypertension,2007,50(2):439~456.
• [7]VALE P R,LOSORDO D W,MILLIKEN C E,et al.Phase 1 placebo-controlled,double-blind,dose-escalating trial ofmyocardial vascular endothelial growth factor 2(VEGF-2)gene transfer utilizing catheter delivery in patients withchronic myocardial ischemia[J].Circulation,2001,104(17):1214.
• [8]ENGELHARDT S,GRIMMER Y,FAN G H,et al.Constitutive activity of the human beta(1)-adrenergic receptor inbeta(1)-receptor transgenic mice[J].Molecular Pharmacology,2001,60(4):712~717.
• [9]WILLIAMS M L,HATA J A,SCHRODER J,et al.Targeted beta~adrenergic receptor kinase(beta ARK1)inhibitionby gene transfer in failing human hearts[J].Circulation,2004,109(13):1590~1593.
• [10]HOSHIJIMA M.Gene therapy targeted at calcium handling as an approach to the treatment of heart failure[J].Phar-macology&Therapeutics,2005,105(3):211~228.
• [11]MOST P,PLEGER S T,VOLKERS M,et al.Cardiac adenoviral S100A1 gene delivery rescues failing myocardium[J].Journal of Clinical Investigation,2004,114(11):1550~1563.
• [12]HUQ F,LEBECHE D,LYER V,et al.Gene transfer of parvalbumin improves diastolic dysfunction in senescent myo-cytes[J].Circulation,2004,109(22):2780~2785.
• [13]MCCRORY P.Super athletes or gene cheats[J].British Journal of Sports Medicine,2003,37(3):192~193.
• [14]BARTON-DAVIS E R,SHOTURMA D I,MUSARO A,et al.Viral mediated expression of insulin-like growth factor Iblocks the aging-related loss of skeletal muscle function[J].Proceedings of the National Academy of Sciences of theUSA,1998,95(26):15603~15607.
• [15]HACEIN-BEY-Abina S,LEDEIST F,CARLIER F,et al.Sustained correction of X-linked severe combined immunodeiciency by exvivo gene therapy[J].New England Journal of Medicine,2002,346(16):1185~1193.
• [16]ZENG H,LI J,LIU J P,et al.Exchange-coupled nanocomposite magnets by nanoparticle self-assembly[J].Nature,2002,420(6914):395~398.
• [17]BOGDANOVICH S,KRAG T O,BARTON E R,et al.Founctiollal improvement of dystrophic muscle by mystatinblockade[J].Nature,2002,420(6914):395~398.
• [18]SMITH O.Biomedicine-Pain-killer genes[J].Science,1999,284(5420):1634.
• [19]MUZZIN P,EISENSMITH R C,COPELAND K C,et al.Correction of obesity and diabetes in genetically obese miceby leptin gene therapy[J].Proceedings of the National Academy of Sciences of the USA,1996,93(25):14804~14808.
• [20]WANG X D,LIU J,YANG J C,et al.Mice body weight gain is prevented after naked human leptin cDNA transfer intosketetal muscle by etectroporation[J].Journal of Gene Medicine,2003,5(11):966~976.